ERR2208960
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- COMPLEMENT+0.300
- IL2_STAT5_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- ADIPOGENESIS+0.200
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- APICAL_SURFACE-0.200
- E2F_TARGETS-0.200
- MYC_TARGETS_V2-0.200
- MYOGENESIS-0.200
- PANCREAS_BETA_CELLS-0.200
- SPERMATOGENESIS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- COAGULATION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-75-5122-01A-01R-1755-07 | — | cohortA1 | 0.858 |
| 2 | SRR8518287 | — | C | 0.835 |
| 3 | TCGA-44-2656-01A-02R-0946-07 | — | cohortA1 | 0.829 |
| 4 | SRR934884 | — | — | 0.821 |
| 5 | SRR25617885 | — | C | 0.820 |
| 6 | SRR4195658 | — | — | 0.817 |
| 7 | 526e2e75-cc0e-4c03-916c-908fbc271854 | — | — | 0.802 |
| 8 | SRR8518388 | — | D | 0.797 |
| 9 | SRR1369148 | GTEX | — | 0.797 |
| 10 | BS_479S95Q6 | Schwannoma | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |